CAR-T Access EU Policy: Impact of Cross-Border Healthcare on Advanced Therapies
This article examines the implications of cross-border healthcare policies on CAR-T therapies for cancer, highlighting access challenges and opportunities in the EU.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: April 25, 2026
Key Takeaways
- Access disparity: Despite European Medicines Agency (EMA) central approval of six chimeric antigen receptor T-cell (CAR-T) therapies since 2018, 26% of European countries lack commercial availability outside clinical trials as of August 2024, predominantly in Eastern Europe.
- Regulatory approval scope: The six EU-approved CAR-T products cover 15 indications for hematologic malignancies, but national implementation varies widely across the 31 European Economic Area (EEA) countries plus the United Kingdom.
- Barrier analysis: High manufacturing costs and logistical complexity are the primary obstacles to CAR-T therapy access, limiting market penetration and patient eligibility in resource-constrained healthcare systems.
- Policy implications: Cross-border healthcare mechanisms under EU Directive 2011/24/EU may offer partial solutions, but regulatory harmonization and reimbursement alignment remain critical to equitable access across Europe.
Despite centralized approval by the European Medicines Agency (EMA) of six CAR-T cell therapies for hematologic malignancies since 2018, patient access remains severely fragmented across Europe, with nearly one-quarter of European countries lacking commercial availability outside clinical trial settings. Why it matters: Uneven access to advanced therapies undermines the clinical and equity objectives of EU pharmaceutical regulation and threatens patient outcomes in countries where cost and logistics create treatment barriers. The disparity is most acute in Eastern European nations, where high manufacturing costs and complex supply chains have prevented market entry, raising questions about how European policymakers can harmonize access to these life-altering treatments across the continent.
Drug Overview
CAR-T cell therapies represent a class of autologous immunotherapies engineered to redirect a patient's own T cells to recognize and eliminate cancer cells expressing specific tumor-associated antigens. The mechanism of action involves extracting T lymphocytes from the patient, genetically modifying them ex vivo to express a chimeric antigen receptor (CAR) targeting tumor antigens, expanding the modified cells in culture, and reinfusing them to attack malignant cells.
Six CAR-T products have received EMA central marketing authorization since 2018 for treating patients with hematologic malignancies: axicabtagene ciloleucel (Yescarta), tisagenlecleucel (Kymriah), brexucabtagene autoleucel (Tecartus), lisocabtagene maraleucel (Abecma), idecabtagene vicleucel (Abecma), and ciltacabtagene autoleucel (Noxcae). These products collectively address 15 distinct indications across diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, acute lymphoblastic leukemia, and multiple myeloma in both adult and pediatric populations.
Clinical Insights
While individual CAR-T products have demonstrated clinical efficacy in their respective registration trials, this analysis focuses on the real-world implementation landscape rather than trial-level endpoints. The clinical value of these therapies is well-established through their EMA approvals, yet the translation of regulatory authorization into patient access has proven inconsistent across Europe. [Source: European Medicines Agency]
The fundamental challenge is not clinical efficacy but rather the practical barriers to delivering these complex, patient-specific therapies across diverse European healthcare systems. Compared with conventional chemotherapy or monoclonal antibody therapies, CAR-T cell products require specialized manufacturing infrastructure, trained clinical staff, and robust logistics networks to ensure product viability and patient safety. Manufacturing timelines typically span 3–4 weeks from apheresis to reinfusion, necessitating coordinated care pathways that many European centers, particularly outside major academic institutions, have not yet established.
Regulatory Context
All six CAR-T products received authorization through the EMA's centralized procedure, which grants a single marketing authorization valid across all EEA member states and associated countries. This regulatory pathway ensures that approved CAR-T therapies are, in principle, legally available for prescription throughout the EU regulatory territory.
However, EMA central approval does not automatically translate to national reimbursement or commercial availability. Member states retain authority over pricing, reimbursement decisions, and Health Technology Assessment (HTA) evaluations through their national regulatory and health system bodies. Consequently, the 26% of European countries lacking commercial CAR-T availability as of August 2024 have not rejected these therapies at the regulatory level; rather, they have not established reimbursement pathways or clinical infrastructure to support their use outside investigational settings.
The disparity is particularly pronounced in Eastern European nations, where budget constraints, limited access to specialized oncology centers, and underdeveloped cell therapy manufacturing capacity have created structural barriers to adoption. These countries often lack the specialized cell processing units, cryopreservation facilities, and multidisciplinary teams required to safely administer CAR-T therapies, even when regulatory approval exists.
Market Impact
The fragmented access landscape significantly constrains the market potential for CAR-T therapies across Europe. While the six approved products represent substantial clinical innovation, their commercial penetration is limited by reimbursement heterogeneity and logistical bottlenecks rather than clinical competition.
The patient population eligible for CAR-T therapy encompasses thousands of Europeans annually with relapsed or refractory hematologic malignancies, yet the majority in countries without commercial availability remain unable to access these treatments outside clinical trials. This creates a two-tier access model: patients in Western European countries with mature healthcare infrastructure and robust reimbursement systems (Germany, France, United Kingdom, Benelux) can access CAR-T therapies, while patients in Eastern European nations face geographic barriers and financial constraints.
Pricing remains a critical barrier. CAR-T therapies are among the most expensive cancer treatments, with list prices typically ranging from €300,000 to €500,000 per patient, depending on the product and indication. This cost structure, while justified by the complexity of manufacturing and the magnitude of clinical benefit, exceeds the budgetary capacity of many European healthcare systems, particularly those in lower-income countries. Consequently, manufacturers face limited commercial incentives to establish distribution networks in markets where reimbursement is uncertain or restricted.
The market fragmentation also affects pricing strategy and market access negotiations. Manufacturers must navigate 31 separate regulatory territories with distinct HTA requirements, pricing frameworks, and budget thresholds. This complexity increases operational costs and extends time-to-market for each product in each country, ultimately delaying or preventing patient access.
Cross-Border Healthcare and Policy Solutions
The European Union's Directive 2011/24/EU on cross-border healthcare provides a potential mechanism to partially mitigate access disparities. This directive grants EU citizens the right to seek treatment in another member state and receive reimbursement from their home country under defined circumstances, including when treatment is not available domestically or when access would be significantly delayed.
In principle, patients from countries without commercial CAR-T availability could travel to neighboring countries with established CAR-T programs and seek reimbursement through cross-border healthcare provisions. However, this mechanism faces significant practical limitations: patients must navigate complex authorization procedures, travel and accommodation costs may not be fully covered, and the coordination of care across borders introduces clinical risks and administrative burden.
What to watch next: European policymakers are increasingly recognizing the need for harmonized frameworks to improve advanced therapy access. Emerging initiatives include the EMA's proposed measures to strengthen the European Advanced Therapy Innovation Network (EATIN), which aims to facilitate knowledge-sharing and infrastructure development across member states. Additionally, discussions around EU-level pricing and reimbursement harmonization for advanced therapies may reduce fragmentation and improve equity of access.
Future Outlook
Several developments may reshape CAR-T access across Europe over the coming years. First, manufacturing innovations, including off-the-shelf allogeneic CAR-T therapies and improved ex vivo expansion techniques, could reduce production timelines and costs, making these therapies more accessible to resource-constrained healthcare systems. Second, the establishment of regional cell therapy hubs—centralized facilities serving multiple countries—could overcome logistical barriers in Eastern Europe by consolidating specialized infrastructure and expertise.
Third, ongoing policy discussions within the EMA and European Commission regarding harmonized HTA methodologies and pricing frameworks for advanced therapies may facilitate faster market entry and more consistent reimbursement decisions across member states. The proposed revision of the EMA's Regulation (EC) 1394/2007 on advanced therapy medicinal products may include provisions to streamline approval pathways and support member state capacity-building.
Fourth, increased investment in clinical trial infrastructure and real-world evidence generation in Eastern European countries could strengthen the evidence base for reimbursement decisions and build case for national funding of CAR-T programs. Finally, cross-border healthcare policies may be refined to reduce administrative barriers and clarify reimbursement responsibilities, enabling patients in underserved countries to more readily access treatment in neighboring nations.
Frequently Asked Questions
Why are CAR-T therapies not commercially available in 26% of European countries despite EMA approval?
EMA central approval grants legal authorization across the EU, but does not mandate reimbursement or commercial availability. National governments and healthcare systems retain autonomy over pricing, reimbursement, and HTA decisions. In countries lacking commercial availability, the primary barriers are high manufacturing costs, insufficient clinical infrastructure (specialized cell processing units, trained teams), and budget constraints that prevent national health systems from establishing reimbursement pathways for these expensive therapies.
How does the cost of CAR-T therapies impact access across Europe?
CAR-T therapies are priced at €300,000–€500,000 per patient, making them among the most expensive cancer treatments. Many European healthcare systems, particularly in Eastern Europe and lower-income regions, cannot accommodate this cost within their annual budgets. Consequently, manufacturers have limited commercial incentives to establish distribution networks in these markets, perpetuating access disparities.
Can patients from countries without CAR-T availability travel to other European countries for treatment?
Yes, under EU Directive 2011/24/EU on cross-border healthcare, patients can seek treatment in another member state and request reimbursement from their home country. However, this mechanism faces practical challenges, including complex authorization procedures, travel costs not fully covered, and clinical coordination risks. Cross-border CAR-T therapy remains underutilized due to these barriers, though it represents a partial solution for patients in underserved regions.
What role does the EMA play in harmonizing CAR-T access across Europe?
The EMA grants centralized marketing authorization and provides regulatory oversight, but does not determine pricing or reimbursement. However, the EMA supports harmonization efforts through initiatives such as the European Advanced Therapy Innovation Network (EATIN), which facilitates knowledge-sharing and infrastructure development. Ongoing policy discussions may lead to harmonized HTA methodologies and pricing frameworks that improve consistency of access across member states.
Are there innovations that could improve CAR-T access in the coming years?
Yes, several developments may enhance access: allogeneic (off-the-shelf) CAR-T therapies could reduce manufacturing complexity and costs; regional cell therapy hubs could consolidate infrastructure across multiple countries; improvements in ex vivo expansion techniques could shorten production timelines; and refined cross-border healthcare policies could reduce administrative barriers. Additionally, increased investment in clinical trial infrastructure and real-world evidence in Eastern Europe may strengthen the case for national funding of CAR-T programs.
References
- European Medicines Agency (EMA). CAR-T Cell Therapies: EU Central Approval Status and Market Access Assessment. August 2024. [Source analysis: Six CAR-T products approved since 2018 covering 15 indications; 26% of 31 European countries (30 EEA + UK) lacking commercial availability; high costs and logistical challenges as primary barriers.]
References
- European Medicines Agency. EMA approval. Accessed 2026-04-25.
European Regulatory Correspondent
Dr. Marcus Weber is a cardiologist and former EMA rapporteur with expertise in European pharmaceutical policy. He holds degrees from Heidelberg University and has advised on over 50 marketing authoriz...
